| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00185-0933-87 | 00185-0933 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Sep 23, 2014 | Nov 21, 2015 | No Longer Used |
| 54569-6168-02 | 54569-6168 | Ondansetron, ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 9, 2016 | In Use | |
| 83008-0026-10 | 83008-0026 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 12, 2023 | Jun 30, 2026 | In Use |
| 00078-0248-15 | 00078-0248 | cyclosporine | NeOral | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Jul 14, 1995 | In Use | |
| 00078-0110-22 | 00078-0110 | Cyclosporine | Sandimmune | 100.0 mg/mL | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Nov 14, 1983 | Dec 31, 2025 | In Use |
| 49884-0868-02 | 49884-0868 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Jun 30, 2008 | Feb 29, 2020 | In Use |
| 42254-0077-30 | 42254-0077 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 2, 2007 | In Use | |
| 58118-0458-05 | 58118-0458 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Jun 26, 2017 | No Longer Used |
| 55513-0924-91 | 55513-0924 | Filgrastim | Neupogen | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct 2, 2000 | In Use | |
| 52584-0069-00 | 52584-0069 | ONDANSETRON | ONDANSETRON | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jul 3, 2018 | Nov 30, 2023 | No Longer Used |
| 68462-0106-33 | 68462-0106 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 23155-0550-31 | 23155-0550 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 9, 2015 | In Use | |
| 65293-0373-25 | 65293-0373 | ONDANSETRON HYDROCHLORIDE | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 18, 2009 | Jan 31, 2015 | In Use |
| 76282-0412-05 | 76282-0412 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 22, 2015 | In Use | |
| 00781-5238-06 | 00781-5238 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 19, 2011 | Dec 31, 2020 | In Use |
| 00006-3862-13 | 00006-3862 | Aprepitant | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Mar 26, 2003 | In Use | |||
| 55111-0154-78 | 55111-0154 | Ondansetron Hydrochloride | ONDANSETRON | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
| 83980-0013-13 | 83980-0013 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 19, 2025 | In Use | |
| 82449-0201-01 | 82449-0201 | Ondansetron hydrochloride | Ondansetron hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sep 30, 2023 | In Use | |
| 61703-0325-18 | 61703-0325 | Pamidronate Disodium | Pamidronate Disodium | 6.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jul 28, 2003 | In Use | ||
| 82448-0100-14 | 82448-0100 | Nirogacestat | OGSIVEO | 100.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | Ɣ Secretase Inhibitor | Oral | Nov 27, 2023 | In Use | |
| 51655-0415-43 | 51655-0415 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 28, 2017 | In Use | |
| 00069-1311-10 | 00069-1311 | epoetin alfa-epbx | RETACRIT | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Nov 9, 2020 | In Use | ||
| 67046-0346-03 | 67046-0346 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 8, 2024 | In Use | |
| 00069-1340-05 | 00069-1340 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | May 10, 2011 | May 31, 2014 | No Longer Used |
Found 11888 results — Export these results
Home